Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade.

Jacobsen JS, Comery TA, Martone RL, Elokdah H, Crandall DL, Oganesian A, Aschmies S, Kirksey Y, Gonzales C, Xu J, Zhou H, Atchison K, Wagner E, Zaleska MM, Das I, Arias RL, Bard J, Riddell D, Gardell SJ, Abou-Gharbia M, Robichaud A, Magolda R, Vlasuk GP, Bjornsson T, Reinhart PH, Pangalos MN.

Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8754-9. doi: 10.1073/pnas.0710823105. Epub 2008 Jun 16.

2.

Dose-dependent thrombus resolution due to oral plaminogen activator inhibitor (PAI)-1 inhibition with tiplaxtinin in a rat stenosis model of venous thrombosis.

Baxi S, Crandall DL, Meier TR, Wrobleski S, Hawley A, Farris D, Elokdah H, Sigler R, Schaub RG, Wakefield T, Myers D.

Thromb Haemost. 2008 Apr;99(4):749-58. doi: 10.1160/TH07-11-0669.

PMID:
18392333
3.

Novel 1-(azacyclyl)-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines as 5-HT6 agonists and antagonists.

Elokdah H, Li D, McFarlane G, Bernotas RC, Robichaud AJ, Magolda RL, Zhang GM, Smith D, Schechter LE.

Bioorg Med Chem. 2007 Sep 15;15(18):6208-26. Epub 2007 Jun 14.

PMID:
17624788
4.

Neutralization of plasminogen activator inhibitor I (PAI-1) by the synthetic antagonist PAI-749 via a dual mechanism of action.

Gardell SJ, Krueger JA, Antrilli TA, Elokdah H, Mayer S, Orcutt SJ, Crandall DL, Vlasuk GP.

Mol Pharmacol. 2007 Oct;72(4):897-906. Epub 2007 Jul 10.

PMID:
17622579
5.

Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor.

Gorlatova NV, Cale JM, Elokdah H, Li D, Fan K, Warnock M, Crandall DL, Lawrence DA.

J Biol Chem. 2007 Mar 23;282(12):9288-96. Epub 2007 Feb 2.

6.

Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis.

Smith LH, Dixon JD, Stringham JR, Eren M, Elokdah H, Crandall DL, Washington K, Vaughan DE.

Blood. 2006 Jan 1;107(1):132-4. Epub 2005 Sep 13.

7.

Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis.

Hennan JK, Elokdah H, Leal M, Ji A, Friedrichs GS, Morgan GA, Swillo RE, Antrilli TM, Hreha A, Crandall DL.

J Pharmacol Exp Ther. 2005 Aug;314(2):710-6. Epub 2005 Apr 28.

PMID:
15860572
8.

Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling.

Weisberg AD, Albornoz F, Griffin JP, Crandall DL, Elokdah H, Fogo AB, Vaughan DE, Brown NJ.

Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):365-71. Epub 2004 Dec 2.

PMID:
15576638
9.

Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy.

Crandall DL, Elokdah H, Di L, Hennan JK, Gorlatova NV, Lawrence DA.

J Thromb Haemost. 2004 Aug;2(8):1422-8.

10.

Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization.

Elokdah H, Abou-Gharbia M, Hennan JK, McFarlane G, Mugford CP, Krishnamurthy G, Crandall DL.

J Med Chem. 2004 Jul 1;47(14):3491-4.

PMID:
15214776
11.

Design, synthesis, and biological evaluation of thio-containing compounds with serum HDL-cholesterol-elevating properties.

Elokdah H, Sulkowski TS, Abou-Gharbia M, Butera JA, Chai SY, McFarlane GR, McKean ML, Babiak JL, Adelman SJ, Quinet EM.

J Med Chem. 2004 Jan 29;47(3):681-95.

PMID:
14736248
12.

WAY-140312 reduces plasma PAI-1 while maintaining normal platelet aggregation.

Crandall DL, Hennan JK, Elokdah H, Krishnamurthy G, Antrilli TM, Bauer JS, Morgan GA, Swillo RE.

Biochem Biophys Res Commun. 2003 Nov 28;311(4):904-8.

PMID:
14623266
13.

Mapping of a conformational epitope on plasminogen activator inhibitor-1 by random mutagenesis. Implications for serpin function.

Gorlatova NV, Elokdah H, Fan K, Crandall DL, Lawrence DA.

J Biol Chem. 2003 May 2;278(18):16329-35. Epub 2003 Feb 26.

14.

Novel human metabolites of the angiotensin-II antagonist tasosartan and their pharmacological effects.

Elokdah HM, Friedrichs GS, Chai SY, Harrison BL, Primeau J, Chlenov M, Crandall DL.

Bioorg Med Chem Lett. 2002 Aug 5;12(15):1967-71.

PMID:
12113820
15.

Design and synthesis of tricyclic derivatives as high density lipoprotein cholesterol enhancers.

Elokdah H, Chai SY, Ho D, Sulkowski T.

Bioorg Med Chem Lett. 2001 Feb 12;11(3):339-42.

PMID:
11212105
16.

Effects of 2-(substituted-sulfanyl)-3,5-dihydro-imidazole-4-one and 2-(substituted-sulfanyl)-1H-imidazole-4,5-dione derivatives on serum HDL-cholesterol.

Elokdah H, Sulkowski T, Cochran D, McKean ML, Quinet E.

Bioorg Med Chem Lett. 2000 Aug 21;10(16):1791-4.

PMID:
10969969

Supplemental Content

Loading ...
Support Center